5 Exhibitors to Visit at CPHI Worldwide Milan 2026

Paid placement disclosure. These exhibitor sections are paid Shared Spotlight placements. Inclusion is not an award, ranking, or TradeShowIntel endorsement, and it does not affect independent Floor Picks.Disclosure version 2026-09

Why a planned route matters at CPHI Worldwide Milan 2026

CPHI Worldwide returns to Fiera Milano in Rho from 6 to 8 October 2026, spreading thousands of exhibitors across a multi-hall campus that takes the better part of a day to traverse end to end. The sheer scale of the event, one of the largest annual gatherings in the global pharmaceutical supply chain, makes unplanned walking an inefficient strategy for buyers with specific sourcing or evaluation goals.

The five companies featured in this guide, BASF, IMA TMC, GEA Group, Evonik Corporation, and Brenntag Ingredients (India) Private Limited, collectively address a range of buyer jobs that often arise in a single procurement cycle: sourcing catalysts and API intermediates, evaluating functional excipients and drug delivery platforms, scoping CDMO partners, assessing contained solid dosage equipment, and identifying documented specialty ingredient channels for regulated markets. Visiting them as a grouped route on day one allows a buyer to benchmark across complementary categories before the hall traffic peaks.

Why these exhibitors

A set built around common pharmaceutical sourcing and evaluation jobs

These five companies are not presented as the only worthwhile exhibitors at CPHI Worldwide Milan 2026. They are grouped here because their combined scope addresses several buyer jobs that frequently appear together in pharmaceutical procurement and development planning. A formulation scientist evaluating excipient suppliers will find relevant stops at BASF and Evonik Corporation. A CDMO evaluation team can engage GEA Group on equipment scope and Evonik Corporation on drug product services within the same morning. A procurement manager sourcing documented excipients for regulated Indian markets has a focused conversation available at Brenntag Ingredients (India) Private Limited. A manufacturing engineer assessing packaging automation can evaluate IMA TMC independently of the chemistry-focused stops. The route is designed so that each visit informs the next without requiring backtracking across unrelated hall segments.

How to use this Shared Spotlight

Download booth locations before you arrive Confirm stand numbers in the official CPHI 2026 exhibitor directory. Confirmed locations in this guide are Hall 12, stand 12M33 for BASF and Hall 12, stand A49 for Evonik Corporation, and Hall 9, stand 9A66 for GEA Group. Check the directory for IMA TMC and Brenntag Ingredients (India) before the show opens.
Anchor your morning in Hall 12 Hall 12 holds two confirmed stands in this set. Begin with BASF at 12M33 and move to Evonik Corporation at A49 before foot traffic in the hall builds. Both conversations centre on excipient and API chemistry, so back-to-back visits allow direct comparison of portfolios and service models.
Cross to Hall 9 for equipment evaluation After Hall 12, move to Hall 9 and visit GEA Group at stand 9A66. Equipment discussions typically require more time, so scheduling this visit before lunch, when the stand team is freshest, is advisable.
Confirm and close with distribution and packaging Use confirmed booth locations from the show directory to locate IMA TMC and Brenntag Ingredients (India) Private Limited. These two stands complete the route by covering end-of-line packaging automation and specialty excipient distribution, respectively.

Floor-planning tip Block ninety minutes for Hall 12 in the first session of day one, sixty minutes for Hall 9 before the midday break, and reserve a final thirty-minute window in the afternoon to revisit any stand where a follow-up conversation was interrupted.

TL;DR

5 stops worth planning

Suggested floor route

Hall 12 to Hall 9, chemistry before equipment

Starting in Hall 12 with BASF and Evonik Corporation, then crossing to Hall 9 for GEA Group, keeps the two longest walks of the day in sequence and avoids the need to re-enter either hall after the midday crowd builds.

1BASFPrioritize this stand if you are an API synthesis chemist or procurement manager sourcing pharmaceutical-grade building blocks, catalysts for key synthesis steps, or mass-balance certified raw materials to meet sustainability commitments.Hall 12 · 12M33
2IMA - TMC SPAPrioritize contacting IMA TMC if you are a tissue converter or absorbent hygiene product manufacturer evaluating end-of-line automation from primary wrapping through palletizing, particularly where a transition to recyclable packaging materials is under consideration.
3GEA GroupPrioritize this stand if you are a pharmaceutical manufacturer or CDMO evaluating contained solid dosage equipment, continuous film coating, or single-use downstream processing and want to assess a single supplier capable of covering multiple unit operations across the same project.Hall 9 · 9A66
4Evonik CorporationPrioritize this stand if you are a formulation scientist or biopharma development lead sourcing oral or parenteral excipients, evaluating ready-to-fill functional capsule formats for sensitive actives, or scoping a CDMO partner for API through commercial drug product.Hall 12 · A49
5Brenntag Ingredients (India) Private LimitedPrioritize this stand if you are a pharmaceutical or biopharma procurement manager sourcing fully documented excipients, amino acids, or mineral salts for regulated formulation work in or through India.

BASF

BASF Pharma Solutions supplies functional excipients, active pharmaceutical ingredients, and digital formulation services for oral, topical, soft-gel, and biologic drug products.

Booth12M33Hall 12

Read company profilePrioritize this stand if you are an API synthesis chemist or procurement manager sourcing pharmaceutical-grade building blocks, catalysts for key synthesis steps, or mass-balance certified raw materials to meet sustainability commitments.Read more

About

BASF SE, headquartered in Ludwigshafen am Rhein, Germany and founded in 1865, operates one of the broadest chemical portfolios in the industry. Its pharmaceutical-facing businesses supply high-purity intermediates, reagents and solvents used as building blocks in API synthesis, precious-metal catalyst technologies for pharmaceutical manufacturing steps, and sodium nitrite, nitrate, and related monomers. The company employs 108,251 people worldwide as of December 31, 2025.

BASF holds a top-three market position across every active strategic business area within its Nutrition and Health division, supported by a vertically integrated Verbund production network that spans sites in Bishop (Texas), Callanish (UK), and Sandefjord (Norway). Its excipients portfolio includes Kollidon, Kollicoat, and Soluplus, the last of which is now monographed in the European Pharmacopoeia and activated on China DMF, removing the novel-excipient burden for oral applications in both markets. The company also supplies AvaPur, a reusable resin for one-step antibody capture and purification in downstream bioprocessing.

At CPHI Worldwide Milan 2026

At CPHI Worldwide Milan 2026, BASF is presenting in the Contract Manufacturing and Services zone at stand 12M33 in Hall 12. The stand focuses on the company's role as a supply partner to API manufacturers, covering its Intermediates range of pharmaceutical-grade building blocks, reagents, and solvents, its GREEn platform of sustainable precious-metal catalysts including blocking group removal catalysts for pharmaceutical synthesis, and its Monomers portfolio of sodium nitrite, nitrate, sodium, and potassium products. Visitors can also explore the company's Biomass Balance (BMBcert) and Ccycled mass-balance product offerings, which address sustainability requirements in pharmaceutical production supply chains.

GREEn platform: sustainable precious-metal catalysts for pharmaceutical synthesis stepsBlocking Group Removal catalysts designed for API manufacturing workflowsBiomass Balance (BMBcert) and Ccycled mass-balance product lines for sustainability documentationPharmaceutical-grade intermediates, reagents, and solvents as synthesis building blocksSoluplus monographed in the European Pharmacopoeia and activated on China DMFPrecious-metal catalystsAPI intermediatesSustainable chemistryExcipients

Why visit

Prioritize this stand if you are an API synthesis chemist or procurement manager sourcing pharmaceutical-grade building blocks, catalysts for key synthesis steps, or mass-balance certified raw materials to meet sustainability commitments.

What to ask at the booth

Which excipient grades do you recommend for a poorly soluble API in an immediate-release tablet?
Can you provide regulatory documentation and DMF/CEP support for Kollidon and Soluplus?
What are your lead times and regional supply options for ibuprofen and omega-3 API grades?
How does the Virtual Pharma Assistants platform work for early-stage formulation screening?
What capacity do you have at the new Wyandotte GMP Solution Center for bioprocessing ingredients?

IMA - TMC SPA

Automatic primary and secondary packaging machines and end-of-line systems for Tissue rolls and Absorbent Personal Care products.

Read company profilePrioritize contacting IMA TMC if you are a tissue converter or absorbent hygiene product manufacturer evaluating end-of-line automation from primary wrapping through palletizing, particularly where a transition to recyclable packaging materials is under consideration.Read more

About

IMA TMC (Tissue Machinery Company S.p.A.) is headquartered in Castel Guelfo, Bologna, Italy, and has operated since 1997 as a specialist in automatic packaging and handling machinery for tissue and nonwoven products. The company builds wrapping and bundling machines, high-speed stackers and baggers, and robotic end-of-line palletizing systems for converters producing toilet paper, kitchen towels, facial tissues, napkins, baby diapers, adult briefs, and incontinence products. Since 2018 it has operated as part of IMA Group's Tissue and Nonwoven division, with subsidiary operations in North America and Brazil extending its production and service reach.

A notable capability is the ability to run sustainable primary packaging materials, including paper and 100% recyclable polyethylene, at the same throughput as conventional films, with wrapping lines rated to 250 packs per minute. The company holds ISO 9001:2015, ISO 45001:2018, and ISO 14001 certifications covering quality, occupational health and safety, and environmental management. Its palletizing systems feature a patented NEST gripping head that lifts products from below, reducing contact pressure and product damage compared with top-contact handling approaches.

At CPHI Worldwide Milan 2026

IMA TMC is the Tissue and Nonwoven packaging division of IMA Group and does not appear among the confirmed exhibitors at CPHI Worldwide Milan 2026. The IMA Group presence at this show is represented by its pharmaceutical entities. Buyers attending CPHI who work in tissue converting or absorbent hygiene product manufacturing and wish to discuss wrapping, bagging, or palletizing lines should contact IMA TMC directly via the company website to arrange a separate meeting or identify the appropriate regional team.

Wrapping and bundling lines rated to 250 packs per minute for single- and multi-layer tissue roll configurationsStackers and baggers for baby diapers, adult briefs, light incontinence products, and bed underpadsPatented NEST gripping head palletizing system for gentle, zero-pressure end-of-line handlingPaper and 100% recyclable polyethylene primary packaging compatibility at full production speedISO 9001:2015, ISO 45001:2018, and ISO 14001 certifications across quality, safety, and environmental managementTissue packagingEnd-of-line automationSustainable packagingAbsorbent hygiene

Why visit

Prioritize contacting IMA TMC if you are a tissue converter or absorbent hygiene product manufacturer evaluating end-of-line automation from primary wrapping through palletizing, particularly where a transition to recyclable packaging materials is under consideration.

What to ask at the booth

What is the maximum throughput of your wrapping lines for multi-layer tissue roll configurations?
Can your machines run 100% recyclable PE or paper primary packaging at the same speed as traditional films?
Do you offer local production and spare-parts support in North America and Brazil for tissue converters?
How does the NEST gripping head compare in terms of product damage versus vacuum-based palletizing systems?
What is the typical lead time and commissioning support for a full wrapping-to-palletizing line?

GEA Group

Supplier of pharmaceutical process equipment and lines spanning tablet presses, pharma separators, spray dryers, continuous processing, and freeze-drying automation.

Booth9A66Hall 9

Read company profilePrioritize this stand if you are a pharmaceutical manufacturer or CDMO evaluating contained solid dosage equipment, continuous film coating, or single-use downstream processing and want to assess a single supplier capable of covering multiple unit operations across the same project.Read more

About

GEA Group Aktiengesellschaft, headquartered in Düsseldorf, Germany and founded in 1881, is a DAX-listed mechanical and plant engineering group with approximately 18,000 employees and EUR 5.4 billion in FY2024 revenue. Its pharmaceutical division supplies process equipment and complete manufacturing lines covering oral solid dosage, biopharmaceutical downstream processing, aseptic powder handling, and lyophilization across more than 150 countries.

GEA holds a notable position in biopharmaceutical separation: the company reports that every second pharma separator used for vaccines and novel biopharmaceuticals is a GEA machine. Its ALUS freeze-drying automation technology has been installed at more than 350 production-scale sites worldwide, backed by seven patents and more than 35 years of validated field history. The ConsiGma continuous tableting platform, co-developed with Hovione, extends that depth into continuous solid dosage manufacturing.

With the introduction of the PERFORMA D in India, we are not only introducing another tablet press but also offering manufacturers a powerful new tool for producing complex bilayer formulations and high-volume products.

At CPHI Worldwide Milan 2026

At CPHI Milan 2026 in Hall 9 (stand 9A66), GEA is presenting equipment from its contained powder transfer and continuous solid dosage lines. Featured products confirmed for the show include the BUCK® AC and BUCK® MC split valves for contained powder transfer in high-potency applications, the ConsiGma® FC Flex and ConsiGma® FC Lab continuous film coaters, and the NexGen Press® 30 modular tablet press. Visitors can discuss how these systems fit into contained, continuous, or high-volume batch manufacturing configurations.

BUCK® AC and MC split valves for contained, high-potency powder transferConsiGma® FC Flex and FC Lab continuous film coaters for solid dosage linesNexGen Press® 30 modular tablet press for flexible oral solid dosage productionkytero® single-use disk-stack separator line (kytero 10 through kytero 2000) for cell harvesting and clarificationALUS freeze-drying automation with 350+ production-scale installed systems and 7 patentsContained powder transferContinuous film coatingTablet pressSingle-use bioprocessing

Why visit

Prioritize this stand if you are a pharmaceutical manufacturer or CDMO evaluating contained solid dosage equipment, continuous film coating, or single-use downstream processing and want to assess a single supplier capable of covering multiple unit operations across the same project.

What to ask at the booth

What is the maximum output and billet capability of the PERFORMA D press for my specific tablet formulation?
Can the kytero single-use separator scale from lab (kytero 10) to production (kytero 2000) for my cell line and process?
Do you provide validation and qualification support for fully contained installations for high-potency or oncology APIs?
How does the ConsiGma CDC Flex continuous direct compression system integrate with existing batch lines?
What service and aftermarket support do you offer for pharma separator and tablet press lines in my region?

Evonik Corporation

Leading global provider of functional excipients, drug delivery technologies, and CDMO services for oral and parenteral pharmaceutical dosage forms.

Booth12A49Hall 12

Read company profilePrioritize this stand if you are a formulation scientist or biopharma development lead sourcing oral or parenteral excipients, evaluating ready-to-fill functional capsule formats for sensitive actives, or scoping a CDMO partner for API through commercial drug product.Read more

About

Evonik Industries AG, headquartered in Essen, Germany, operates its Health Care business unit across drug delivery, drug substance, and biopharma ingredients. The portfolio spans EUDRAGIT® functional polymer excipients for oral solid dosage forms, EUDRACAP® ready-to-fill functional capsules for targeted delivery, RESOMER® bioresorbable polymers for extended-release parenterals, and PhytoSquene®, a GMP-quality plant-derived squalene for parenteral applications. The company employs approximately 31,000 people globally and reported €14.1 billion in sales in 2025.

EUDRAGIT® polymers have been cited in more than 23,000 patents and are used in formulations sold in over 80 countries, giving Evonik a reference base that few excipient suppliers can match. The company also operates as a CDMO capable of handling APIs and HPAPIs alongside its own excipient supply, covering custom synthesis through commercial drug product manufacturing. EUDRACAP® colon won the CPHI Pharma Award 2025 in the Finished Formulation category, and PhytoSquene® won the CPHI Pharma Award 2024 in Sustainability, both recognitions tied directly to CPHI's own jury process.

We are incredibly proud that EUDRACAP® colon has been recognized with a CPHI Award. By offering a solution for sensitive actives, while also simplifying formulation development and enabling faster clinical entry, EUDRACAP® colon will help to bring breakthrough therapies to patients sooner.

At CPHI Worldwide Milan 2026

At CPHI Milan 2026, Evonik's Health Care business is presenting EUDRACAP® colon functional capsules, currently in GMP pre-launch, as the first ready-to-fill capsule targeting the ileo-colonic region for sensitive actives including biologics and RNA therapeutics. Visitors can also review PhytoSquene® plant-based squalene, the full EUDRAGIT® oral excipients portfolio across immediate, delayed, and controlled release grades, and parenteral drug delivery solutions covering lipids and bioabsorbable polymers for injectable programs. CDMO capability discussions spanning API synthesis, HPAPI handling, and commercial parenteral manufacturing are available at the stand.

EUDRACAP® colon: first ready-to-fill functional capsule for ileo-colonic targeting, GMP pre-launch stagePhytoSquene®: plant-derived, GMP-quality squalene replacing shark-sourced material in parenteral formulationsEUDRAGIT® polymer portfolio: 70-plus years of oral delivery history, 23,000-plus patent citations across 80-plus countriesRESOMER® bioresorbable polymers for extended-release parenteral and implantable drug deliveryIntegrated CDMO services: API, HPAPI, formulation development, and commercial drug product manufacturingOral drug deliveryParenteral excipientsCDMO servicesFunctional capsules

Why visit

Prioritize this stand if you are a formulation scientist or biopharma development lead sourcing oral or parenteral excipients, evaluating ready-to-fill functional capsule formats for sensitive actives, or scoping a CDMO partner for API through commercial drug product.

What to ask at the booth

Which EUDRAGIT® grade is best suited for our target release profile and API stability window?
Can EUDRACAP® colon capsules reduce formulation timelines for our sensitive biologic or RNA program?
Do you offer lipid nanoparticle and custom lipid supply for mRNA and gene therapy, including scale-up?
What parenteral extended-release excipients and CDMO capabilities do you have for complex injectables?
Can you provide end-to-end CDMO support from custom synthesis through commercial manufacturing for our API or HPAPI?

Brenntag Ingredients (India) Private Limited

Distributor of specialty ingredients and excipients for pharmaceutical, nutraceutical, food and industrial applications across India, a subsidiary of Brenntag SE.

Read company profilePrioritize this stand if you are a pharmaceutical or biopharma procurement manager sourcing fully documented excipients, amino acids, or mineral salts for regulated formulation work in or through India.Read more

About

Brenntag Ingredients (India) Private Limited is headquartered in Andheri East, Mumbai, and incorporated in 2005 as the Indian subsidiary of Brenntag SE, which operates roughly 600 distribution sites across more than 70 countries from its base in Essen, Germany. The Indian entity serves pharmaceutical, nutraceutical, food, and industrial customers with a portfolio that spans qualified amino acids, pharmaceutical-grade titanium dioxide, citric acids and citrates, and mineral salts.

The India business recorded revenue of approximately INR 1,236 crore in FY2025, representing around 27 percent year-on-year growth, and was recognized for achieving the highest country sales growth within Brenntag Specialties across Asia Pacific in FY2022. Dedicated Innovation and Application Centres provide formulation and scale-up support directly to customers, and the company holds membership in the Responsible Care initiative covering health, safety, and environmental standards.

We define precision in everything we do — from sourcing high-purity excipients, salts, and amino acids to enabling next-generation technologies such as 3D printing.

At CPHI Worldwide Milan 2026

No booth assignment for CPHI Worldwide Milan 2026 has been confirmed in available research. At CPHI India 2025, Brenntag showcased its Qualified Amino Acids Portfolio alongside pharmaceutical-grade titanium dioxide, citric acids and citrates, and mineral salts under the Excipients category. Visitors to CPHI Worldwide Milan can expect the India team to present a similar excipient and specialty ingredient scope relevant to formulators and procurement teams working with regulated pharmaceutical markets.

Qualified Amino Acids Portfolio with full regulatory documentation for API, excipient, buffer, and cell-culture applicationsPharmaceutical-grade titanium dioxide meeting compendial standards for excipient useCitric acids and citrate salts for solid-dose and liquid pharmaceutical formulationHigh-purity mineral salts for pharmaceutical and nutritional applicationsInnovation and Application Centres offering direct technical formulation support in IndiaPharma ExcipientsAmino AcidsMineral SaltsSpecialty Distribution

Why visit

Prioritize this stand if you are a pharmaceutical or biopharma procurement manager sourcing fully documented excipients, amino acids, or mineral salts for regulated formulation work in or through India.

What to ask at the booth

Which amino acids in your qualified portfolio carry DMF or CEP documentation for use as APIs versus excipients?
Can you supply compendial-grade material (USP, EP, BP, IP) and provide CoAs for titanium dioxide, citrates, and mineral salts?
What technical support can your Innovation and Application Centres provide for formulation or scale-up projects targeting the Indian market?
What are your lead times, minimum order quantities, and import versus locally stocked options for pharmaceutical excipients?
How do you support biopharma upstream cell-culture and downstream buffer preparation with documented amino acids?

Before you leave the hall

Capture notes while context is fresh

At the close of each stand visit, record the name and direct contact of the person you spoke with, the specific product lines or service scopes discussed, and any follow-up materials promised. CPHI Worldwide generates a high volume of business card exchanges, and without stand-level notes the details of individual conversations blur within twenty-four hours.

For a broader view of exhibitors, session programming, and venue logistics at CPHI Worldwide Milan 2026, the TradeShowIntel event page consolidates sourced details in one place.

CPHI Worldwide Milan 2026 on TradeShowIntel Official CPHI Worldwide website

Frequently asked questions

Planning this CPHI Worldwide Milan 2026 route

When and where is CPHI Worldwide Milan 2026?

CPHI Worldwide Milan 2026 runs from 6 to 8 October 2026 at Fiera Milano in Rho, Italy, a large exhibition campus accessible by metro from central Milan via the M1 line to Rho Fiera station.

Which halls should a pharmaceutical buyer prioritize on day one?

Hall 12 and Hall 9 are the two halls that contain confirmed stands for the exhibitors in this guide. Hall 12 concentrates excipient and API chemistry suppliers, while Hall 9 covers pharmaceutical process equipment. Buyers focused on formulation sourcing and equipment evaluation should plan to cover both halls on the first day.

Who is this guide written for?

This guide is written for pharmaceutical and biopharma buyers, including formulation scientists, procurement managers, CDMO evaluation teams, and manufacturing engineers, who want to make deliberate use of limited floor time at a large event rather than walking the show without a plan.

How do I get in touch with the exhibitors featured here?

Each exhibitor card in this Shared Spotlight includes stand location details where confirmed. For exhibitors without a listed booth number, check the official CPHI 2026 exhibitor directory on the CPHI website before the show opens, or contact the company directly through their corporate website to arrange a meeting in advance.

Are these the only exhibitors worth visiting at CPHI Worldwide Milan 2026?

No. CPHI Worldwide is one of the largest pharmaceutical trade events in the world and features exhibitors across a wide range of categories. The five companies in this guide represent paid placements and are grouped because their combined scope is useful for a specific set of buyer jobs. Buyers should consult the full exhibitor directory to identify additional stops relevant to their sourcing agenda.